Study shows no link between response rates and survival in myeloma

Results of a meta-regression analysis have shown that, contrary to popular opinion, there is no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in newly diagnosed myeloma patients. Published recently in the European Journal of Haematology, the researchers explored the relationship between response to initial…

Details

New UK guidelines for managing the “late effects” of myeloma and its treatment

Myeloma UK together with the British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) have jointly published new guidelines for the screening and management of the late and long-term consequences of myeloma and its treatments. Published recently in the British Journal of Haematology, the guidelines highlight the key late effects…

Details

Myeloma XI publication reports on incidence of SPM following Revlimid® maintenance treatment

Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…

Details

Myeloma UK funded research identifies mechanism for genetic risk of myeloma

A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…

Details

Study reveals prevalence of symptoms in myeloma patients

A Myeloma UK funded study, published recently in the European Journal of Haematology, has found that a large number of symptoms occur frequently in myeloma patients, highlighting the importance of routine assessments throughout the disease trajectory in order to achieve optimal quality of life for patients. Led by Christina Ramsenthaler and Prof Irene Higginson, Department of…

Details

Revamped Cancer Drugs Fund launched in England

A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…

Details